The 5-year survival rate for GBC is 13%, and the median survival time is less than 1 year
Image: Figure 7. Hypothetical pattern of melatonin in gallbladder cancer cells. see more
Image source: Corresponding author: Shi Xiaojing Email: shixiaojing@zzu.edu.cn Zhai Wenlong Email: fcczhaiwl@zzu.edu.cn
Aging-US published "Melatonin inhibits proliferation, migration and invasion by inhibiting the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells to induce ROS-mediated cell apoptosis." The indole compounds secreted by the fruit body play a vital role in regulating the circadian rhythm and cancer treatment.
However, the role of melatonin in gallbladder cancer and its related mechanisms remain unclear. The results show that melatonin inhibits the growth, migration and invasion of gallbladder cancer cells. Subsequently, analysis showed that melatonin significantly induced apoptosis in gallbladder cancer cells and changed the expression of apoptotic proteins, including Bax, Bcl-2, cytochrome C, cleaved caspase-3 and PARP.
Treatment with N-acetyl-L-cysteine or 740 YP significantly reduced the anti-tumor effect of melatonin in NOZ and GBC-SD cells. Finally, melatonin inhibits the growth of GBC-SD cells in an in vivo athymic nude mouse xenograft model.
Dr. Shi Xiaojing and Dr. Zhai Wenlong said: “Gall bladder cancer is the most aggressive and common pathological type among the widely reported biliary tract cancers.”
Unfortunately, most patients with gallbladder cancer are diagnosed at an advanced stage because the patient has metastases and other symptoms in the advanced stage.
A previous study reported that the 5-year survival rate for GBC was 13%, and the median survival time was less than 1 year. Therefore, there is an urgent need for new drugs and therapeutic targets for inoperable GBC patients.
The synthesis and secretion of melatonin is controlled by light/night clock, which means that light inhibits the synthesis of melatonin, and darkness stimulates its production. After hydroxylation and decarboxylation, tryptophan synthesizes serotonin, which is regulated by tryptophan hydroxylase and decarboxylase. Serotonin is then acetylated, methylated and converted into melatonin in the pineal gland.
Recently, more and more evidences have shown that melatonin can inhibit tumorigenesis, metastasis and drug resistance of a variety of cancers. By reducing the expression of iNOS and COX-2, melatonin limits the damaging effects of inflammation, thereby inhibiting the tumor progression of breast cancer. Melatonin destroys the formation of tumor blood vessels in renal adenocarcinoma by lowering VEGF. However, the relationship between melatonin and gallbladder cancer has not been clearly established.
These authors evaluated the inhibitory effect of melatonin on the proliferation of gallbladder cancer cells.
The Shi/Zhai research team concluded in their Aging-US research results: “This study shows that melatonin inhibits the proliferation, migration and invasion of gallbladder cancer cells. From a mechanism perspective, melatonin promotes ROS mediation in vitro. Further studies have shown that melatonin inhibits the phosphorylation of PI3K/Akt/mTOR signaling pathway (Figure 7). In addition, melatonin also inhibits tumor growth in vivo without significant toxicity. Overall In other words, melatonin may be an effective and novel treatment candidate for gallbladder cancer."
Full text-https://www.aging-us.com/article/203561/text
Correspondent: Shi Xiaojing Email: shixiaojing@zzu.edu.cn Zhai Wenlong Email: fcczhaiwl@zzu.edu.cn
Keywords: Melatonin, Apoptosis, PI3K/Akt, ROS, Gallbladder carcinoma
Aging-US was launched in 2009 and publishes papers of general interest and biological significance in all areas of aging research and topics other than traditional gerontology, including but not limited to cell and molecular biology, human age-related diseases, and model pathology students Objects, cancers, signal transduction pathways (such as p53, sirtuins, PI-3K/AKT/mTOR, etc.), and methods to regulate these signal pathways.
To learn more about Aging-US, please visit http://www.Aging-US.com or contact @AgingJrnl
Aging-US is published by Impact Journals, LLC, please visit http://www.ImpactJournals.com or contact @ImpactJrnls
Media Contact 18009220957x105 MEDIA@IMPACTJOURNALS.COM
Copyright © 2021 Impact Journals, LLC Impact Journals is a registered trademark of Impact Journals, LLC
"Melatonin inhibits proliferation, migration and invasion by inhibiting the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells to induce ROS-mediated apoptosis"
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted to EurekAlert!! Use any information through contributing agencies or through the EurekAlert system.
RYAN JESSUP Impact Journals LLC RYANJAMESJESSUP@IMPACTJOURNALS.COM Office: 800-922-0957 x105
Copyright © 2021 American Association for the Advancement of Science (AAAS)
Copyright © 2021 American Association for the Advancement of Science (AAAS)